



US005585402A

United States Patent [19]**Moncada et al.**[11] **Patent Number:** **5,585,402**[45] **Date of Patent:** **Dec. 17, 1996**[54] **NITRIC OXIDE SYNTHASE INHIBITORS**[75] Inventors: **Salvador E. Moncada; Richard M. J. Palmer**, both of Beckenham, England[73] Assignee: **Glaxo Wellcome Inc.**, Research Triangle Park, N.Y.[21] Appl. No.: **452,367**[22] Filed: **May 26, 1995****Related U.S. Application Data**

[63] Continuation of Ser. No. 997,291, Dec. 23, 1992, abandoned.

[51] **Int. Cl.⁶** **A61K 31/195**[52] **U.S. Cl.** **514/564; 514/565**[58] **Field of Search** **514/564, 565**[56] **References Cited****U.S. PATENT DOCUMENTS**

4,282,217	8/1981	Baglioni et al.	424/240
5,028,627	7/1991	Kilbourn et al.	514/565
5,081,148	1/1992	Braquet et al.	514/162
5,158,883	10/1992	Griffith	435/240.2
5,356,873	10/1994	Mark et al.	514/2

FOREIGN PATENT DOCUMENTS

A10230037	7/1987	European Pat. Off.
WO91/04023	4/1991	WIPO
WO93/00893	1/1993	WIPO

OTHER PUBLICATIONS

CA 118:78331, Nava et al., 1992.

Tissue injury caused by deposition of immune complexes is L-arginine dependent; vol. 88 pp. 6338-6342, Jul. 1991; Medical Sciences; Michael S. Mulligan et al.

Beckman, J. S. The double-edged role of nitric oxide in brain function and superoxide-mediated injury. *J. Dev. Physiol. (Eynsham)*. 15: 53-60, 1991.Li, L. et al. Role of nitric oxide lysis of tumor cells by cytokine-activated endothelial cells. *Cancer Res.* 51: 2531-2535, 1991.Nakaki, T. et al. Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells, *Eur. J. Pharmacol. Mol. Pharmacol. Sect. 3*: 347-353, 1990.Boughton Smith, N. K. et al. Protective effect of S-nitroso-N-acetyl-penicillamine in endotoxin-induced acute intestinal damage in the rat. *Eur. J. Pharmacol.* 191: 485-488, 1990.Hutcheson, I. R. et al. Role of nitric oxide in maintaining vascular integrity in endotoxin-induced acute intestinal damage in the rat. *Br. J. Pharmacol.* 101: 815-820, 1990.Kilbourn, R. G. et al. Reversal of Endotoxin-mediated shock by N^G-methyl-L-arginine, an inhibitor of nitric oxide synthesis. *Biochem. Biophys. Res. Comm.* 172(3): 1132-1138, 1990.Marshall, J. J. et al. Endothelium-derived relaxing factors. A perspective from in vivo data. *Hypertension* 16: 371-386, 1990.Rubanyi, G. M. et al. Cytoprotective function of nitric oxide inactivation of superoxide radicals produced by human leukocytes. *Biochem. Biophys. Res. Commun.* 181: 1392-1397, 1991.Palmer, R. M. J. et al. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. *Br. J. Pharmacol.* 105: 11-12, 1992.Wright, C. E. et al. Protective and pathological roles of nitric oxide in endotoxin shock. *Cardiovasc. Res.* 26: 48-57, 1992.Ialenti, A. et al. Modulation of acute inflammation by endogenous nitric oxide. *Eur. J. Pharmacol.* 211: 177-182, 1992.Bergmann, L. et al. Cytotoxic action of IL-1B against pancreatic islets is mediated via nitric oxide formation and is inhibited by N^G-monomethyl-L-arginine. *Febs (Fed. Eur. Biochem. Soc.) Lett.* 299: 103-106, 1992.Langrehr, J. M. et al. Evidence that nitric oxide production by in-vivo allosensitized cells inhibits the development of allospecific CTL. *Transplantation (Baltimore)* 53:632-640, 1992.Demerle Pallardy, C. et al. Absence of implication of L-arginine/nitric oxide pathway on neuronal cell injury induced by L-glutamate or hypoxia. *Biochem. Biophys. Res. Commun.* 181: 456-464, 1991.Billiar, T. R. et al. Modulation of nitrogen oxide synthesis in vivo: N^G-monomethyl-L-arginine inhibits endotoxin-induced nitrite/nitrate biosynthesis while promoting hepatic damage. *J. Leuk. Biol.* 48: 565-569, 1990.Ochoa, J. B. et al. Nitrogen oxide levels in patients after trauma and during sepsis. *Ann. Surg.* 214: 621-626, 1991.Bone, R. C. The pathogenesis of sepsis. *Ann. Intern. Med.* 115:457-469, 1991.Dal Nogare, A. R. Septic shock. *Am. J. Med. Sci.* 302: 50-65, 1991.

Nava, E. et al. The role of nitric oxide in endotoxic shock. (Corresponds to the poster). (1991).

Rees, D. D. et al. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. *Br. J. Pharmacol.* 96: 418-424, 1989.Sakuma, I. et al. Identification of arginine as a precursor of endothelium-derived relaxing factor. *Proc. Natl. Acad. Sci. USA.* 85: 8664-8667, 1988.Beckman, J. S. et al. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. *Proc. Natl. Acad. Sci. USA.* 87: 1620-1624, 1990.Beckman, J. S. Ischaemic injury mediator. *Nature* 345: 27-28, 1990.

(List continued on next page.)

Primary Examiner—Kimberly Jordan*Attorney, Agent, or Firm*—George W. Neuner[57] **ABSTRACT**

The present invention discloses a method for inhibiting tissue damage in mammals caused by pathological NO production, which comprises administering an effective tissue damage inhibition amount of a NO synthase inhibitor to said mammal. Preferably the NO synthase inhibitor is L-NMMA.

8 Claims, 3 Drawing Sheets